The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens. Urology, 70 (4 Gleason score between isoechoic cancers (mean 5.4) and hypoechoic cancers (mean 5.6). However, hyperechoic cancers had a mean Gleason score of 7.0, which was higher when compared with isoechoic and hypoechoic cancers.
INTRODUCTION
Prostate cancer is a very common entity, with the incidence increasing with age. The majority of these patients are free from symptoms and less than 3% of patients with pathologically confirmed diagnosis die from prostate cancer. 1 The introduction of transrectal ultrasound (TRUS) probe by Wantanabe et al. 2 and development of the diagnostic procedure first applied in 1981 by Holm and Gammelgard 3 have significantly contributed to the early diagnosis of prostate cancer. Besides having a major role in positioning the needle trajectory for prostate biopsy, TRUS enables visualization of focal lesions suspected of prostate cancer. [4] [5] [6] [7] [8] A definitive
protocol regarding the number of biopsy cores for prostate biopsy has not yet been established, and the number of cores taken per biopsy varies from 4 to 30. [9] [10] [11] Recently, the average number of biopsies has been gradually increasing, however, the detection rate remains unchanged and the need of repeat biopsy is increasing. Despite the high rate of false negative biopsy findings (20-30%), as reported by Rabbani et al. 12 and Fleshner and al. 13 , sextant biopsies are still in wide use. 14, 15 Hyperechoic lesions are usually considered as benign, whether benign prostate hyperplasia (BPH), prostatitis or prostate infarction. 8 On TRUS, prostate cancer is visualized as a hypoechoic lesion in 60-70%, and as isoechoic lesion in 30-40% of cases. Hyperechoic lesions are rare, with an incidence of approximately 1.5%. [16] [17] [18] [19] Some unusual types of prostatic adenocarcinoma have been reported to appear as hyperechoic lesions, e.g., in case of ductal adenocarcinoma with central necrosis, dysmorphic calcifications and deposition of intraluminal crystals. 16 The aim of this study was to estimate the incidence of TRUS hyperechoic lesions and of hyperechoic prostate cancer in TRUS guided biopsy specimens.
PATIENTS AND METHODS
This prospective study included a series of 200 patients with total PSA <20 ng/mL and/or positive digital rectal examination (DRE), age range 54-78 (mean 67.5) years, PSA 2. 4-19.3 (mean 9.9) ng/mL, and prostate volume 16-78 (mean 37.4) ccm.
All study patients served as both experimental and control group. Each patient underwent TRUS and biopsy. Suspect lesions found on TRUS were classified as hypo-or hyperechoic.
Mixed lesions were considered as hypoechoic TRUS findings.
All patients underwent TRUS guided prostate biopsy and histopathologic findings were compared with TRUS findings.
We used a Siemens SI-400 ultrasound device with biplane transrectal probe Siemens An improved pre-embedding method for all biopsy specimens was applied, as described by Rogatsch et al. 22 Specimens were fixed in 10% buffered formaldehyde, embedded in paraffin, cut at 5 µm thickness, and routinely stained with haematoxylin and eosin. In some cases, the material was stained with p63, HMW-CK and alcian-PAS. Alcian-PAS positive staining was not used as the only criterion since it is well known that such positivity might be seen in mimickers of cancer such as atrophy and adenosis.
Statistical analysis was performed using χ 2 -test and Student's t-test. The level of significance was set at p<0.05.
RESULTS
Results of PSA and TRUS findings in 200 patients were given in Table 1 The mean Gleason score in isoechoic, hyperechoic and hypoechoic cancers was 5.4
(ranged from 4 to 9), 5.6 (ranged from 5 to 9) and 7.0 (ranged from 6 to 9), respectively. There was no statistically significant difference in Gleason score between isoechoic and hypoechoic cancers (p>0.05). In hyperechoic tumors, Gleason score was higher as compared with the other two groups; however, the number of patients in the hyperechoic group was too small for statistical analysis (Table 2) .
COMMENT
It is believed that TRUS guided biopsy is the only accurate preoperative method for early diagnosis of prostate cancer. The average number of biopsies has been gradually increasing, however, sextant biopsies are still widely used.
14,15
In our study, hypoechoic lesions were found in 41.5% and hyperechoic lesions in 9.5% of patients. Forty nine percent of the patients had normal findings on transrectal ultrasound.
We diagnosed cancer in 66 (33.0%) patients; 68.2% of them had focal lesions on TRUS, while 31.8% had normal ultrasound findings. In our study, the number of diagnosed cancers with abnormal TRUS was moderately higher as compared with the study conducted by Vo et al. 23 that diagnosed 62.9% of prostate cancers in patients with abnormal TRUS findings and PSA >4.
Finne et al. 24 studied 200 patients with median PSA value of 13.2 ng/mL and found carcinoma in 26% of patients. We diagnosed a higher number of carcinomas than Finne at al. 24 , where median PSA value was higher than that recorded in our study (13.2 vs. 9.9 ng/mL). Loch et al. 7 report on a 29% rate of prostate cancer in patients with PSA >4. The patients included in their study had no limited PSA value. In our study, all patients had PSA <20, and we diagnosed a higher percentage of prostate cancers compared to Loch et al. 7 The higher percentage of cancer detected in our study could probably be ascribed to additional biopsies that were obtained in hyperechoic lesions, where another five carcinomas were identified.
There was no statistically significant correlation between serum PSA values and ultrasound findings. The mean PSA value in patients with abnormal TRUS findings was almost the same as the mean value recorded in patients with normal ultrasound findings (10.1 ng/mL vs.
9.8 ng/mL). Also, we found no significant difference between PSA value in hyperechoic, hypoechoic and isoechoic carcinoma.
Review of the literature shows very rare findings of prostate cancer originating in hyperechoic lesions. The reported incidence is 1-1.5%. [16] [17] [18] [19] Egawa et al. 16 performed transrectal ultrasonography prior to radical prostatectomy in 157 patients with prostate cancer and hyperechoic cancers were diagnosed in only two (1.3%) patients. Shinohara et al. 17 diagnosed 70
carcinomas, of which only one was hyperechoic (1.4%). Malika et al. 18 performed biopsy in 100 patients suspected of carcinoma and diagnosed 23 carcinomas, none of which was hyperechoic.
They also found and submitted to biopsy 11 hyperechoic lesions but none of them was diagnosed as carcinoma. Stilmant and Kuligowska 19 report on only one prostate cancer originating from a hyperechoic lesion. Our findings in 19 patients with hyperechoic lesions, five of them with diagnosed carcinoma (7.6% of all diagnosed carcinomas in our study) indicated a higher rate of hyperechoic cancers than that reported in the literature. [16] [17] [18] [19] Of the 5 patients with hyperechoic cancer, 3 underwent radical prostatectomy, which confirmed diagnosis, 1 was treated with radiation therapy and 1 recived androgen ablation therapy.
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confirmed that Gleason score was independent of ultrasound findings, but biopsies were done on hypoechoic lesions. In our study, the mean Gleason score of carcinoma in patients with hypoechoic lesions and normal ultrasound findings was not significantly different, but carcinomas in patients with hyperechoic lesions had a higher mean
Gleason score. Distribution of Gleason score in patients with hyperechoic carcinoma was equal to or greater than the median for all patients together (n = 66). In patients with isoechoic and hypoechoic carcinoma, an approximately equivalent number of patients was distributed below and above the median.
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CONCLUSIONS
Based on our study, we concluded that hyperechoic lesions were positive for prostate cancer in a higher percentage of patients than previously reported in the literature and suggest that additional biopsy of hyperechoic lesions be included in the protocol for prostate biopsy. This procedure, which includes a greater number of cores is well tolerated, has a minimal rate of complications, and should be part of the standard protocol in urological practice. 26, 27 Additional studies are needed to determine the exact rate of hyperechoic cancer and the respective Gleason score. 
